Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has changed its name from Celly Nutrition Corp. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4] - The company is a non-trading but fully reporting public issuer focused on wellness and recovery supplements, specifically the unbuzzd beverage that aids in alcohol metabolism [8][9] - Unbuzzd has been scientifically validated through a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in accelerating alcohol metabolism and reducing hangover symptoms [9] Group 2: Financial and Audit Information - MNP LLP, a PCAOB-registered audit firm, has been engaged to conduct audits for Unbuzzd Wellness Inc. to ensure compliance and readiness for a possible IPO [2][3] - The previous auditor, Stern & Lovrics LLP, resigned at the company's request, and MNP was appointed based on the audit committee's recommendation [1][3] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history for the most recent financial year [3] Group 3: Leadership and Strategic Direction - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments from unbuzzd sales until a total of $250 million is reached [6]

Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has engaged MNP LLP to conduct PCAOB audits effective May 20, 2025, to ensure compliance and readiness for a possible IPO [1][2] - The company has changed its name to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4][5] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history [3] Group 2: Product Information - Unbuzzd is a scientifically-proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, appealing to a broad audience of alcohol consumers [8][9] - The product has been validated by a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in speeding up alcohol metabolism and reducing symptoms of intoxication [9] Group 3: Leadership Insights - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] Group 4: Ownership and Financial Structure - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments from sales until reaching $250 million, after which the royalty rate will drop to 3% [6]

Core Viewpoint - Quantum BioPharma Ltd. has received approval for a Phase 2 clinical trial of FSD202, aimed at assessing its safety and efficacy in treating chronic widespread musculoskeletal nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) [1][4]. Group 1: Clinical Trial Details - The trial will enroll 60 patients with idiopathic MCAS, where participants will receive either FSD202 or a placebo twice daily for 56 days [1]. - The primary outcome will measure the decrease in average daily pain intensity from baseline to Day 28 [1]. - Secondary outcomes will also be evaluated during the trial [1]. Group 2: Drug Information - FSD202 contains ultra-micronized palmitoylethanolamide (PEA) and has potential applications for a variety of inflammatory diseases beyond MCAS [2]. - Chronic inflammatory diseases are a leading cause of death globally, with the World Health Organization identifying chronic disease as a significant health threat [2]. Group 3: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition, which is involved in the development of the OTC product unbuzzd™ [4]. - Quantum BioPharma has a royalty agreement with Celly Nutrition, receiving 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% indefinitely [4].

Core Viewpoint - Quantum BioPharma Ltd. has partnered with BitGo Trust Company to manage and store its cryptocurrency assets, including Bitcoin, Solana, XRP, and DOGE coin, enhancing its security and compliance as a public company [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [3]. Partnership with BitGo - BitGo will provide institutional-grade custody services, including multi-signature wallets and 100% cold storage technology, to protect Quantum's cryptocurrency assets from theft and unauthorized access [2]. - The partnership aligns with Quantum's priorities for security and compliance as it expands its engagement with cryptocurrency assets [2][3]. Industry Context - The collaboration with BitGo reflects a broader trend where institutions like Quantum are shaping the future of digital finance, emphasizing the need for secure and compliant infrastructure [3][5]. - BitGo is recognized as a leading provider of digital asset solutions, serving thousands of institutions and handling a significant portion of Bitcoin network transactions [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a global pharmaceutical contract research organization to prepare an IND application package for Lucid-21-302 (Lucid-MS) with the US FDA, aiming to initiate a Phase 2 trial for multiple sclerosis (MS) [1][3] - Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a key factor in MS and other neurodegenerative diseases [2] - The company plans to submit the IND application to the FDA in Q4 2025, marking a significant step towards advancing its treatment for MS [3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, that has shown potential in preclinical models [4] - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which is involved in the marketing of unbuzzd™, and has established a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Core Viewpoint - Quantum BioPharma Ltd. has strategically increased its investment in Bitcoin and other cryptocurrencies, reflecting confidence in their potential for returns and as a hedge against the Canadian dollar [1][2]. Group 1: Cryptocurrency Investment - The company has purchased an additional USD $1,000,000 worth of Bitcoin and other cryptocurrencies, bringing the total investment to USD $4,500,000 [1]. - Quantum BioPharma plans to continue allowing financing and transactions in cryptocurrencies, indicating a commitment to integrating digital assets into its operations [2]. Group 2: Compliance and Custodianship - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. - The company will actively monitor market conditions to adjust its cryptocurrency holdings as deemed appropriate [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at treating multiple sclerosis [4]. - The company retains a 20.11% ownership stake in Celly Nutrition, which includes a royalty agreement for sales from its product unbuzzd™ [4].

Core Viewpoint - Quantum BioPharma Ltd. is actively participating in two upcoming conferences to engage with institutional investors and showcase its innovative biopharmaceutical solutions [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis, currently in preclinical development [4]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [4]. Conference Participation - Jason Sawyer, the Head of Finance and M&A, will represent Quantum BioPharma at the Sidoti Micro-Cap Conference on May 21, 2025, and the A.G.P. Virtual Healthcare Conference on May 22, 2025 [2][3]. - At the Sidoti Micro-Cap Conference, Sawyer will host one-on-one meetings with institutional investors and deliver a webcast presentation [2][3].

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].

Company Overview - Quantum BioPharma Ltd. is hosting a Business Update Conference Call on May 6, 2025, at 04:30 PM ET, led by its Founder and CEO, Zeeshan Saeed, and Head of Finance and M&A, Jason Sawyer [1][5]. Forward-Looking Statements - The conference call may include forward-looking statements that represent the company's current judgment on future events, which are subject to risks and uncertainties that could lead to actual results differing materially [2][4]. - Participants are cautioned not to place undue reliance on these forward-looking statements, as they reflect opinions only as of the date of the presentation [3].

Core Viewpoint - Quantum BioPharma Ltd. has filed an amended complaint alleging market manipulation by several banks, seeking damages exceeding $700 million USD due to the alleged manipulation of its stock price through "spoofing" techniques from January 2020 to August 2024 [1][2][3]. Group 1: Legal Proceedings - The amended complaint was filed on May 1, 2025, in response to a Motion to Dismiss from the banks [1]. - The lawsuit claims that CIBC World Markets and RBC Dominion Securities, among others, violated the Securities Exchange Act of 1934 [1][2]. - The law firms Christian Attar and Freedman Normand Friedland LLP are representing the company on a contingency basis, alleviating financial pressure for legal costs [2]. Group 2: Allegations of Market Manipulation - The complaint alleges that the defendants engaged in "spoofing" techniques that artificially depressed Quantum BioPharma's stock price [2]. - The company asserts that the stock was trading over $460 USD per share in January 2020, with a market capitalization nearing $1 billion USD [3]. - Quantum BioPharma believes that additional banks and brokers may also be involved in the alleged manipulation but will not disclose their names until more evidence is gathered [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [7]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [8]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which includes a royalty agreement on sales from its product unbuzzd™ [8].